Layoffs
The facility is expected to close by the end of 2020, affecting 270 staffers, with 80 possible redundancies.
Five Prime Therapeutics will eliminate 70 jobs as the company undergoes a restructuring to extend its cash runway. Five Prime said the restructuring plan will save an estimated $20 million in annualized cost savings.
BioSpace scanned the WARN (Worker Adjustment and Retraining Notification) notices across the country and compiled a small list of recent layoffs across the industry.
Less than a month after its Phase III brain cancer treatment failed, San Diego-based Tocagen is undergoing a company restructuring and will reduce its workforce by approximately 65%, the company announced late Thursday.
More than 600 employees will lose their jobs as the companies reshape their corporate strategies.
In addition to the layoffs, Acer said it has halted pre-commercial activities surrounding Edsivo due to the FDA’s rejection last month.
A month after beleaguered Merrimack Pharmaceuticals announced it was terminating its staff and leadership team, the company’s chief executive officer and chief financial officer have resigned their positions. But, they are both remaining with the company as high-paid consultants.
Financial details of the deal were not disclosed, but Lonza said it plans to retain the Novartis employees currently working at the facility.
Two months after taking over as interim chief executive officer of Bay Area-based uBiome, John Rakow is stepping down from the company that has been under scrutiny from the Federal Bureau of Investigation (FBI).
Following an operational review, ImmunoGen will prioritize continued development of mirvetuximab, as well as a select portfolio of three earlier-stage product candidates.
PRESS RELEASES
